Andra AP fonden Acquires 48,327 Shares of West Pharmaceutical Services, Inc. $WST

Andra AP fonden raised its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 723.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 55,007 shares of the medical instruments supplier’s stock after buying an additional 48,327 shares during the period. Andra AP fonden’s holdings in West Pharmaceutical Services were worth $13,787,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in WST. Empowered Funds LLC boosted its holdings in shares of West Pharmaceutical Services by 16.1% in the 1st quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock valued at $361,000 after buying an additional 224 shares during the last quarter. Intech Investment Management LLC raised its position in West Pharmaceutical Services by 27.7% during the first quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock worth $1,348,000 after acquiring an additional 1,307 shares in the last quarter. Acadian Asset Management LLC raised its position in West Pharmaceutical Services by 14.1% during the first quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after acquiring an additional 157 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in West Pharmaceutical Services by 78.2% in the second quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock valued at $98,000 after acquiring an additional 197 shares during the last quarter. Finally, First Trust Advisors LP grew its position in shares of West Pharmaceutical Services by 168.4% in the 2nd quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock valued at $10,137,000 after acquiring an additional 29,067 shares during the period. 93.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on WST. Wolfe Research initiated coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They issued an “outperform” rating and a $375.00 target price on the stock. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Morgan Stanley upped their price objective on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Finally, KeyCorp boosted their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $363.17.

West Pharmaceutical Services Stock Up 2.0%

WST opened at $359.32 on Wednesday. The stock has a fifty day moving average of $334.27 and a 200-day moving average of $286.00. The company has a market capitalization of $25.39 billion, a P/E ratio of 48.04, a P/E/G ratio of 2.85 and a beta of 1.16. West Pharmaceutical Services, Inc. has a fifty-two week low of $211.10 and a fifty-two week high of $367.66. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. The company had revenue of $844.90 million during the quarter, compared to the consensus estimate of $779.67 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm’s quarterly revenue was up 21.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, equities analysts expect that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current year.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This trade represents a 37.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares in the company, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.60% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.